Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax

The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10−4) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax–rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7/67) and 11.9% (8/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R/R CLL.

[1]  R. Moia,et al.  MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL. , 2022, Blood.

[2]  S. Slager,et al.  Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia , 2022, British journal of haematology.

[3]  S. Bens,et al.  Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia , 2022, HemaSphere.

[4]  Matthew E. Ritchie,et al.  Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy , 2022, Blood.

[5]  R. Herwig,et al.  Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies , 2022, Blood.

[6]  U. Jaeger,et al.  Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab , 2022, Blood.

[7]  E. Thompson,et al.  Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors , 2021, Blood advances.

[8]  M. Hallek,et al.  Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures , 2021, American journal of hematology.

[9]  E. Thompson,et al.  Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition , 2021, Blood advances.

[10]  P. Csermely,et al.  Screening and monitoring of the BTKC481S mutation in a real‐world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy , 2021, British journal of haematology.

[11]  V. Seshan,et al.  Tumor Targeted Nanoparticles Improve Therapeutic Index of BCL2 and MCL1 dual inhibition. , 2020, Blood.

[12]  K. Nasserinejad,et al.  Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. , 2020, Blood.

[13]  U. Jaeger,et al.  Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Kipps,et al.  Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[15]  A. Zelenetz,et al.  Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. , 2020, Blood advances.

[16]  A. Roberts,et al.  BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. , 2020, Blood.

[17]  J. Byrd,et al.  Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. , 2020, Blood.

[18]  J. Byrd,et al.  Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study , 2020, Clinical Cancer Research.

[19]  E. Thompson,et al.  Multiple BCL2 mutations co-occurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. , 2020, Blood.

[20]  P. Blombery Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease , 2020, Leukemia & lymphoma.

[21]  J. Waring,et al.  Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy , 2019, Blood.

[22]  E. Thompson,et al.  Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax , 2019, Blood.

[23]  M. Peifer,et al.  Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.) , 2019, Haematologica.

[24]  Christopher J. Ott,et al.  Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. , 2019, Cancer cell.

[25]  L. Bullinger,et al.  Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia , 2019, Haematologica.

[26]  J. Gribben,et al.  Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Kipps,et al.  Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. , 2019, The New England journal of medicine.

[28]  E. Thompson,et al.  Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. , 2018, Cancer discovery.

[29]  F. Bosch,et al.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. , 2018, Blood.

[30]  R. Greil,et al.  Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study , 2018, Blood.

[31]  M. Davids,et al.  Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) , 2018, Blood.

[32]  Jean Louis Fournier,et al.  Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next‐generation sequencing , 2018, Human mutation.

[33]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[34]  A. Zelenetz,et al.  Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States , 2018, Haematologica.

[35]  G. Gordon,et al.  Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jeffrey A Jones,et al.  Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. , 2018, Blood.

[37]  Marco Montillo,et al.  Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia , 2018, The New England journal of medicine.

[38]  M. Peifer,et al.  Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia , 2018, Nature Communications.

[39]  K. Stamatopoulos,et al.  ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation , 2018, Leukemia.

[40]  Jeffrey A Jones,et al.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.

[41]  B. Cheson,et al.  Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients , 2017 .

[42]  S. Lade,et al.  Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. , 2017, Blood.

[43]  K. Stamatopoulos,et al.  Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations , 2017, Leukemia.

[44]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[45]  L. Laurenti,et al.  BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. , 2016, Blood.

[46]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[47]  R. Emerson,et al.  A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study , 2015, Leukemia.

[48]  J. Martinez-Climent,et al.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. , 2014, Blood.

[49]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[50]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.